Dec. 2 at 7:36 AM
$OCGN Vs
$BLTE
Belite Bio reports positive Phase 3 data for an oral therapy against Stargardt disease, putting pressure on Ocugen's gene therapy approach. Markets are reassessing the prospects.
The trigger for the current nervousness: Belite Bio has published successful data from its Phase 3 "DRAGON" trial. Tinlarebant, an oral therapy for Stargardt disease, showed promising results. For Ocugen, this is a warning sign. Because even though the news confirms the commercial potential of the Stargardt treatment, it simultaneously raises the bar significantly for new market entrants.
This could also facilitate Ocugen's future FDA discussions.
